en · de · es · fr · pt
semax-notes.peptides1126.com › Faq › Semax �š„分子背景与结构 — Complete Guide

Semax �š„分子背景与结构 — Complete Guide

By Editorial Desk · published 2026-05-17 · last reviewed 2026-06-10 · Faq

semax is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-06-10. Numbers and descriptions here follow the published literature rather than marketing material.

Semax 的分子背景与结构

Semax 是一种人工合成的七肽,氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro,单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物,但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly,Semax 替换了中间两个残基,并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。

该化合物于二十世纪八十年代在俄罗斯被开发,相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性,而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示,这一方向促成了多个相关短肽的合成与筛选,而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。

研发背景与监管地位

Semax 是人工设计的七肽,序列为 Met-Glu-His-Phe-Pro-Gly-Pro,骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性,同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Semax at a glance

PropertyValueNotes
化学类别合成七肽ACTH(4-10) 结构类似物
氨基酸序列Met-Glu-His-Phe-Pro-Gly-Pro单字母写作 MEHFPGP
分子量约 813.9 Da随确切形式和盐型略有变化
常见同义词ACTH(4-10) 类似物俄语文献称 Семакс
开发来源俄罗斯二十世纪八十年代

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Related pages on this site

Semax Origin and Molecular Structure

Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.

Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.

Further detail

NETA has antigonadotropic effects via its progestogenic activity and can dose-dependently suppress gonadotropin and sex hormone levels in women and men. The ovulation-inhibiting dose of NETA is about 0.5 mg/day in women. In healthy young men, NETA alone at a dose of 5 to 10 mg/day orally for 2 weeks suppressed testosterone levels from ~527 ng/dL to ~231 ng/dL (–56%). NETA, also known as norethinyltestosterone acetate, as well as 17α-ethynyl-19-nortestosterone 17β-acetate or 17α-ethynylestra-4-en-17β-ol-3-one 17β-acetate, is a progestin, or synthetic progestogen, of the 19-nortestosterone group, and a synthetic estrane steroid. It is the C17β acetate ester of norethisterone. NETA is a derivative of testosterone with an ethynyl group at the C17α position, the methyl group at the C19 position removed, and an acetate ester attached at the C17β position. In addition to testosterone, it is a combined derivative of nandrolone (19-nortestosterone) and ethisterone (17α-ethynyltestosterone). Chemical syntheses of NETA have been published.

2 Bh + 3 O2 + 2 HCl → 2 BhO3Cl + H2 The longer-lived heavy isotopes of bohrium, produced as the daughters of heavier elements, offer advantages for future radiochemical experiments. Although the heavy isotope 274Bh requires a rare and highly radioactive berkelium target for its production, the isotopes 272Bh, 271Bh, and 270Bh can be readily produced as daughters of more easily produced moscovium and nihonium isotopes.

=== Type 1 diabetes === Insulin degludec was studied as an alternative to insulin glargine as part of a basal-bolus regimen in the BEGIN Basal-Bolus Type 1 trial. 629 participants with type 1 diabetes were randomized in a 3:1 ratio to either insulin degludec (n=472) or insulin glargine (n=157) in addition to mealtime insulin aspart. Participants in the degludec treatment arm were switched from their basal insulin to insulin degludec in a 1:1 ratio, with a 20-30% dose reduction in participants receiving multiple basal doses per day. After 52 weeks, participants treated with insulin degludec produced a similar reduction in HbA1c (0.40% vs. 0.39%) meeting the criteria for noninferiority. Adverse events were similar in the two treatment arms; however, rates of nocturnal hypoglycemia (between midnight and 6am) were 27% lower in participants treated with insulin degludec (3.91 vs. 5.22 episodes per patient-year of exposure, p=0.024). The reduction in the incidence of hypoglycemia was seen as a therapeutic benefit, as hypoglycemia is often a dose limiting toxicity in insulin therapy. A systematic review has compared the use of insulin degludec to that of insulin glargine, insulin detemir and NPH insulin in adults and children diagnosed with type 1 diabetes. This review included Randomized Control Trials (RCTs) with a duration of 24 to 104 weeks and had a total sample of 8784 participants randomized across studies: 2428 participants allocated to NPH insulin; 2889 participants to insulin detemir; 2095 participants to insulin glargine; 1372 participants to insulin degludec.

Sources: en.wikipedia.org

Background from the literature

== Mechanism of action == β-Endorphin acts as an agonist that binds to various types of G protein–coupled receptors (GPCRs), most notably to the mu and kappa opioid receptors. Binding to these receptors prevents the release of Substance P in the case of the peripheral nervous system, and the inhibitory neurotransmitter, GABA, in the central nervous system The receptors are responsible for supra-spinal analgesia. Radiotracer studies show that circulating β-endorphin is not transported across the blood–brain barrier and is rapidly degraded by endothelial peptidases.

Non-depolarizing neuromuscular blockers: Non-depolarizing agents act as competitive inhibitors for acetylcholine. Upon the binding of non-depolarizing neuromuscular blockers, neurotransmission is reduced. Consequently, depolarizing and muscle-contracting effects are decreased. Non-depolarizing neuromuscular blockers are generally reversible, and hence have no permanent effects on acetylcholine receptors.

state to do so. Following the milestone, Scott announced that the state would lift their restrictions. June 15 COVID-19 pandemic California authorities remove the mask mandate for outdoor activities. The nationwide death toll from the virus exceeds 600,000, equal to the annual cancer death toll. June 16 – Texas Governor Greg Abbott signs Texas House Bill 1927, eliminating the requirement for Texas residents to obtain a license to carry handguns either concealed or openly starting September 1, 2021. June 17 Politico obtains a recording of William Braddock, GOP candidate in a Florida congressional seat, threatening to send "a Russian and Ukrainian hit squad" to fellow Republican opponent Anna Paulina Luna to make her "disappear." The House votes, by 268 to 161, to repeal the Authorization for Use of Military Force Against Iraq Resolution of 2002. President Biden signs a bill making Juneteenth an official federal holiday. June 18 – 2021 NBA playoffs: The Los Angeles Clippers advance to their first NBA Conference Finals after a 131–119 victory against the Utah Jazz in game 6, in which they will play the Phoenix Suns. June 19 COVID-19 pandemic: Indiana reports its first case of the Delta variant of COVID-19. The first Juneteenth under federal holiday status is celebrated. June 20 2021 Arizona wildfires – An outbreak of wildfires begins in Arizona due to thunderstorms producing dry lightning coming through the state from June 14 to June 20. Due to the outbreak, as well as fire danger, many national forests in the state of Arizona are closed to the public.

Sources: en.wikipedia.org

Frequently asked questions

Semax 是天然存在的物质吗?

不是。Semax 是完全人工合成的七肽,自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10),但序列经过了替换和延长。

Semax 与 ACTH 是什么关系?

Semax 被描述为 ACTH(4-10) 的结构类似物,两者共享部分序列特征。它保留了该片段的部分神经相关活性方向,但去除了完整片段带来的激素释放效应。二者并非同一物质,也不能互相替代。

为什么 Semax 的序列需要在羧基端延长?

加入的 Pro-Gly-Pro 三肽被普遍认为能提升分子对蛋白水解酶的稳定性。这种设计让短肽在体内维持时间更长。具体延长的程度以及不同组织中是否一致,文献中仍存在不同报告。

Semax 在自然界中存在吗?

不存在。它是依据 ACTH 的一段序列人工设计的分子,天然蛋白质中找不到与之完全相同的七肽。名称属于研究代号,而非天然物质名。

Network